<DOC>
	<DOC>NCT00998881</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.</brief_summary>
	<brief_title>Monotherapy Study of MP-513 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients who are 20 75 years old Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug Patients whose HbA1c is between 6.5% 10.0% Patients who were not administered diabetes therapeutic drugs within 12 weeks before administration of investigational drug. Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc) Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification Patients with serious diabetic complications. Patients who are habitual excessive alcohol consumption. Patients with severe hepatic disorder or severe renal disorder. Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>